The health system developed the model in collaboration with Aiforia. The model identifies 15 different colorectal cancer tissue samples and uses other parameters to create a recurrence risk score, according to a Jan. 2 Aiforia news release.
“The licensing agreement with the Mayo Clinic enables us to market and sell this AI model for colorectal cancer recurrence risk evaluation globally,” Aiforia CEO Jukka Tapaninen said in the news release. “This is an example of many similar AI model co-development projects which are ongoing with the Mayo Clinic and other partners. These will enable us to significantly enrich our product portfolio.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
